Last reviewed · How we verify
Daratumumab and corticosteroid treatment
Daratumumab binds to CD38 on multiple myeloma cells to trigger immune-mediated cell death, while corticosteroids provide immunosuppressive and anti-inflammatory support.
Daratumumab binds to CD38 on multiple myeloma cells to trigger immune-mediated cell death, while corticosteroids provide immunosuppressive and anti-inflammatory support. Used for Multiple myeloma (in combination with corticosteroids).
At a glance
| Generic name | Daratumumab and corticosteroid treatment |
|---|---|
| Also known as | Intervention arm |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Drug class | Monoclonal antibody (CD38-targeting) combined with corticosteroid |
| Target | CD38 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Daratumumab is a monoclonal antibody that targets CD38, a surface antigen highly expressed on multiple myeloma cells, leading to cell death through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Corticosteroids are added to enhance treatment efficacy and manage treatment-related inflammation and immune responses.
Approved indications
- Multiple myeloma (in combination with corticosteroids)
Common side effects
- Infusion-related reactions
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Fatigue
Key clinical trials
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (PHASE1, PHASE2)
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (PHASE2, PHASE3)
- An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (PHASE4)
- Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis (PHASE3)
- A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. (PHASE1, PHASE2)
- A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: